Pacira BioSciences, Inc. (PCRX) |
| 25.76 -0.07 (-0.27%) 08-28 16:00 |
| Open: | 25.74 |
| High: | 26.055 |
| Low: | 25.555 |
| Volume: | 483,551 |
| Market Cap: | 1,013(M) |
| PE Ratio: | 9.91 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 32.31 |
| Resistance 1: | 27.66 |
| Pivot price: | 24.44 |
| Support 1: | 24.65 |
| Support 2: | 22.79 |
| 52w High: | 27.66 |
| 52w Low: | 18.8 |
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
| EPS | 0.350 |
| Book Value | 16.870 |
| PEG Ratio | 11.21 |
| Gross Profit | 14.827 |
| Profit Margin (%) | 1.96 |
| Operating Margin (%) | 6.17 |
| Return on Assets (ttm) | 1.5 |
| Return on Equity (ttm) | 2.0 |
Fri, 21 Aug 2026
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Tue, 18 Aug 2026
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Tue, 18 Aug 2026
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Mon, 17 Aug 2026
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Sun, 09 Aug 2026
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy? - Yahoo Finance
Sat, 08 Aug 2026
Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |